ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Celgene Signs Two Cancer Drug Pacts

by Michael McCoy
October 8, 2012 | APPEARED IN VOLUME 90, ISSUE 41

Celgene will pay $35 million to fund R&D on VentiRx Pharmaceuticals’ VTX-2337, a small-molecule Toll-like receptor 8 agonist being developed as a cancer immunotherapy. During an option period, Celgene will have an exclusive right to acquire the Seattle-based firm. Separately, Celgene will work with the Leukemia & Lymphoma Society to identify and fund promising blood cancer research projects. The pact is the first in a new LLS program of venture philanthropy projects with the drug industry.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment